MALDI imaging mass spectrometry: state of the art technology in clinical proteomics

A decade after its inception, MALDI imaging mass spectrometry has become a unique technique in the proteomics arsenal for biomarker hunting in a variety of diseases. At this stage of development, it is important to ask whether we can consider this technique to be sufficiently developed for routine u...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular & cellular proteomics 2009-09, Vol.8 (9), p.2023-2033
Hauptverfasser: Franck, Julien, Arafah, Karim, Elayed, Mohamed, Bonnel, David, Vergara, Daniele, Jacquet, Amélie, Vinatier, Denis, Wisztorski, Maxence, Day, Robert, Fournier, Isabelle, Salzet, Michel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2033
container_issue 9
container_start_page 2023
container_title Molecular & cellular proteomics
container_volume 8
creator Franck, Julien
Arafah, Karim
Elayed, Mohamed
Bonnel, David
Vergara, Daniele
Jacquet, Amélie
Vinatier, Denis
Wisztorski, Maxence
Day, Robert
Fournier, Isabelle
Salzet, Michel
description A decade after its inception, MALDI imaging mass spectrometry has become a unique technique in the proteomics arsenal for biomarker hunting in a variety of diseases. At this stage of development, it is important to ask whether we can consider this technique to be sufficiently developed for routine use in a clinical setting or an indispensable technology used in translational research. In this report, we consider the contributions of MALDI imaging mass spectrometry and profiling technologies to clinical studies. In addition, we outline new directions that are required to align these technologies with the objectives of clinical proteomics, including: 1) diagnosis based on profile signatures that complement histopathology, 2) early detection of disease, 3) selection of therapeutic combinations based on the individual patient's entire disease-specific protein network, 4) real time assessment of therapeutic efficacy and toxicity, 5) rational redirection of therapy based on changes in the diseased protein network that are associated with drug resistance, and 6) combinatorial therapy in which the signaling pathway itself is viewed as the target rather than any single "node" in the pathway.
doi_str_mv 10.1074/mcp.R800016-MCP200
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2742436</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734039480</sourcerecordid><originalsourceid>FETCH-LOGICAL-h214t-713aa3c39827af7b7e6e45e52f7ec59c08af07ec2c80289c3be7b2720d41bd483</originalsourceid><addsrcrecordid>eNpdkMlOwzAQhi0EYn8BDsg3xCFlvCROOCBVZSlSEYjlHDnupDFK4hC7SH17ggoIOM2vmX--WQg5YjBioORZY7rRYwoALInuJg8cYIPssljEUSZTufmjVbJD9rx_BeDAVLxNdlgmYzbIXfJ0N55d3lLb6IVtF7TR3lPfoQm9azD0q3Pqgw5IXUlDhVT3gQY0Vetqt1hR21JT29YaXdOudwFdY40_IFulrj0efsV98nJ99TyZRrP7m9vJeBZVnMkQKSa0FkZkKVe6VIXCBGWMMS8VmjgzkOoSBslNCjzNjChQFVxxmEtWzGUq9snFmtstiwbnBtvQ6zrv-uGafpU7bfO_ldZW-cK951xJLkUyAE7XgOpf23Q8yz9zIGWcgFDvbPCefA3r3dsSfcgb6w3WtW7RLX2uhAQx_B0G5_HvtX7A308XH5_hhb8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734039480</pqid></control><display><type>article</type><title>MALDI imaging mass spectrometry: state of the art technology in clinical proteomics</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Franck, Julien ; Arafah, Karim ; Elayed, Mohamed ; Bonnel, David ; Vergara, Daniele ; Jacquet, Amélie ; Vinatier, Denis ; Wisztorski, Maxence ; Day, Robert ; Fournier, Isabelle ; Salzet, Michel</creator><creatorcontrib>Franck, Julien ; Arafah, Karim ; Elayed, Mohamed ; Bonnel, David ; Vergara, Daniele ; Jacquet, Amélie ; Vinatier, Denis ; Wisztorski, Maxence ; Day, Robert ; Fournier, Isabelle ; Salzet, Michel</creatorcontrib><description>A decade after its inception, MALDI imaging mass spectrometry has become a unique technique in the proteomics arsenal for biomarker hunting in a variety of diseases. At this stage of development, it is important to ask whether we can consider this technique to be sufficiently developed for routine use in a clinical setting or an indispensable technology used in translational research. In this report, we consider the contributions of MALDI imaging mass spectrometry and profiling technologies to clinical studies. In addition, we outline new directions that are required to align these technologies with the objectives of clinical proteomics, including: 1) diagnosis based on profile signatures that complement histopathology, 2) early detection of disease, 3) selection of therapeutic combinations based on the individual patient's entire disease-specific protein network, 4) real time assessment of therapeutic efficacy and toxicity, 5) rational redirection of therapy based on changes in the diseased protein network that are associated with drug resistance, and 6) combinatorial therapy in which the signaling pathway itself is viewed as the target rather than any single "node" in the pathway.</description><identifier>ISSN: 1535-9476</identifier><identifier>EISSN: 1535-9484</identifier><identifier>DOI: 10.1074/mcp.R800016-MCP200</identifier><identifier>PMID: 19451175</identifier><language>eng</language><publisher>United States: American Society for Biochemistry and Molecular Biology</publisher><subject>Animals ; Clinical Medicine - methods ; Diagnostic Techniques and Procedures ; Disease ; Humans ; Life Sciences ; Proteins - analysis ; Proteomics - methods ; Review ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods</subject><ispartof>Molecular &amp; cellular proteomics, 2009-09, Vol.8 (9), p.2023-2033</ispartof><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>2009 by The American Society for Biochemistry and Molecular Biology, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-1096-5044</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742436/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742436/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19451175$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04456037$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Franck, Julien</creatorcontrib><creatorcontrib>Arafah, Karim</creatorcontrib><creatorcontrib>Elayed, Mohamed</creatorcontrib><creatorcontrib>Bonnel, David</creatorcontrib><creatorcontrib>Vergara, Daniele</creatorcontrib><creatorcontrib>Jacquet, Amélie</creatorcontrib><creatorcontrib>Vinatier, Denis</creatorcontrib><creatorcontrib>Wisztorski, Maxence</creatorcontrib><creatorcontrib>Day, Robert</creatorcontrib><creatorcontrib>Fournier, Isabelle</creatorcontrib><creatorcontrib>Salzet, Michel</creatorcontrib><title>MALDI imaging mass spectrometry: state of the art technology in clinical proteomics</title><title>Molecular &amp; cellular proteomics</title><addtitle>Mol Cell Proteomics</addtitle><description>A decade after its inception, MALDI imaging mass spectrometry has become a unique technique in the proteomics arsenal for biomarker hunting in a variety of diseases. At this stage of development, it is important to ask whether we can consider this technique to be sufficiently developed for routine use in a clinical setting or an indispensable technology used in translational research. In this report, we consider the contributions of MALDI imaging mass spectrometry and profiling technologies to clinical studies. In addition, we outline new directions that are required to align these technologies with the objectives of clinical proteomics, including: 1) diagnosis based on profile signatures that complement histopathology, 2) early detection of disease, 3) selection of therapeutic combinations based on the individual patient's entire disease-specific protein network, 4) real time assessment of therapeutic efficacy and toxicity, 5) rational redirection of therapy based on changes in the diseased protein network that are associated with drug resistance, and 6) combinatorial therapy in which the signaling pathway itself is viewed as the target rather than any single "node" in the pathway.</description><subject>Animals</subject><subject>Clinical Medicine - methods</subject><subject>Diagnostic Techniques and Procedures</subject><subject>Disease</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Proteins - analysis</subject><subject>Proteomics - methods</subject><subject>Review</subject><subject>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods</subject><issn>1535-9476</issn><issn>1535-9484</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkMlOwzAQhi0EYn8BDsg3xCFlvCROOCBVZSlSEYjlHDnupDFK4hC7SH17ggoIOM2vmX--WQg5YjBioORZY7rRYwoALInuJg8cYIPssljEUSZTufmjVbJD9rx_BeDAVLxNdlgmYzbIXfJ0N55d3lLb6IVtF7TR3lPfoQm9azD0q3Pqgw5IXUlDhVT3gQY0Vetqt1hR21JT29YaXdOudwFdY40_IFulrj0efsV98nJ99TyZRrP7m9vJeBZVnMkQKSa0FkZkKVe6VIXCBGWMMS8VmjgzkOoSBslNCjzNjChQFVxxmEtWzGUq9snFmtstiwbnBtvQ6zrv-uGafpU7bfO_ldZW-cK951xJLkUyAE7XgOpf23Q8yz9zIGWcgFDvbPCefA3r3dsSfcgb6w3WtW7RLX2uhAQx_B0G5_HvtX7A308XH5_hhb8</recordid><startdate>200909</startdate><enddate>200909</enddate><creator>Franck, Julien</creator><creator>Arafah, Karim</creator><creator>Elayed, Mohamed</creator><creator>Bonnel, David</creator><creator>Vergara, Daniele</creator><creator>Jacquet, Amélie</creator><creator>Vinatier, Denis</creator><creator>Wisztorski, Maxence</creator><creator>Day, Robert</creator><creator>Fournier, Isabelle</creator><creator>Salzet, Michel</creator><general>American Society for Biochemistry and Molecular Biology</general><general>The American Society for Biochemistry and Molecular Biology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1096-5044</orcidid></search><sort><creationdate>200909</creationdate><title>MALDI imaging mass spectrometry: state of the art technology in clinical proteomics</title><author>Franck, Julien ; Arafah, Karim ; Elayed, Mohamed ; Bonnel, David ; Vergara, Daniele ; Jacquet, Amélie ; Vinatier, Denis ; Wisztorski, Maxence ; Day, Robert ; Fournier, Isabelle ; Salzet, Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h214t-713aa3c39827af7b7e6e45e52f7ec59c08af07ec2c80289c3be7b2720d41bd483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Clinical Medicine - methods</topic><topic>Diagnostic Techniques and Procedures</topic><topic>Disease</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Proteins - analysis</topic><topic>Proteomics - methods</topic><topic>Review</topic><topic>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Franck, Julien</creatorcontrib><creatorcontrib>Arafah, Karim</creatorcontrib><creatorcontrib>Elayed, Mohamed</creatorcontrib><creatorcontrib>Bonnel, David</creatorcontrib><creatorcontrib>Vergara, Daniele</creatorcontrib><creatorcontrib>Jacquet, Amélie</creatorcontrib><creatorcontrib>Vinatier, Denis</creatorcontrib><creatorcontrib>Wisztorski, Maxence</creatorcontrib><creatorcontrib>Day, Robert</creatorcontrib><creatorcontrib>Fournier, Isabelle</creatorcontrib><creatorcontrib>Salzet, Michel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular &amp; cellular proteomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Franck, Julien</au><au>Arafah, Karim</au><au>Elayed, Mohamed</au><au>Bonnel, David</au><au>Vergara, Daniele</au><au>Jacquet, Amélie</au><au>Vinatier, Denis</au><au>Wisztorski, Maxence</au><au>Day, Robert</au><au>Fournier, Isabelle</au><au>Salzet, Michel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MALDI imaging mass spectrometry: state of the art technology in clinical proteomics</atitle><jtitle>Molecular &amp; cellular proteomics</jtitle><addtitle>Mol Cell Proteomics</addtitle><date>2009-09</date><risdate>2009</risdate><volume>8</volume><issue>9</issue><spage>2023</spage><epage>2033</epage><pages>2023-2033</pages><issn>1535-9476</issn><eissn>1535-9484</eissn><abstract>A decade after its inception, MALDI imaging mass spectrometry has become a unique technique in the proteomics arsenal for biomarker hunting in a variety of diseases. At this stage of development, it is important to ask whether we can consider this technique to be sufficiently developed for routine use in a clinical setting or an indispensable technology used in translational research. In this report, we consider the contributions of MALDI imaging mass spectrometry and profiling technologies to clinical studies. In addition, we outline new directions that are required to align these technologies with the objectives of clinical proteomics, including: 1) diagnosis based on profile signatures that complement histopathology, 2) early detection of disease, 3) selection of therapeutic combinations based on the individual patient's entire disease-specific protein network, 4) real time assessment of therapeutic efficacy and toxicity, 5) rational redirection of therapy based on changes in the diseased protein network that are associated with drug resistance, and 6) combinatorial therapy in which the signaling pathway itself is viewed as the target rather than any single "node" in the pathway.</abstract><cop>United States</cop><pub>American Society for Biochemistry and Molecular Biology</pub><pmid>19451175</pmid><doi>10.1074/mcp.R800016-MCP200</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-1096-5044</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1535-9476
ispartof Molecular & cellular proteomics, 2009-09, Vol.8 (9), p.2023-2033
issn 1535-9476
1535-9484
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2742436
source MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry
subjects Animals
Clinical Medicine - methods
Diagnostic Techniques and Procedures
Disease
Humans
Life Sciences
Proteins - analysis
Proteomics - methods
Review
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods
title MALDI imaging mass spectrometry: state of the art technology in clinical proteomics
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A57%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MALDI%20imaging%20mass%20spectrometry:%20state%20of%20the%20art%20technology%20in%20clinical%20proteomics&rft.jtitle=Molecular%20&%20cellular%20proteomics&rft.au=Franck,%20Julien&rft.date=2009-09&rft.volume=8&rft.issue=9&rft.spage=2023&rft.epage=2033&rft.pages=2023-2033&rft.issn=1535-9476&rft.eissn=1535-9484&rft_id=info:doi/10.1074/mcp.R800016-MCP200&rft_dat=%3Cproquest_pubme%3E734039480%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734039480&rft_id=info:pmid/19451175&rfr_iscdi=true